PTS and melanoma: Using MRS, they provide proof that, concomitant with growth inhibition and induction of differentiation, the hsp90 inhibitor, 17-AAG, alters the PTPS of melanoma cells in a predictable manner, leading to no changes in PC and increases in GPC, free fatty acyl chains and cytoplasmic lipid droplets.